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Abstract 
Background: No single and ideal method has been proposed so far to 
decrease the time of mechanical ventilation while maintaining patients' 
hemodynamic stability after coronary bypass surgery. This study aimed to 
compare the effect of Dexmedetomidine and Morphine infusion on the latter 
parameters in patients after coronary artery bypass graft surgery in the 
intensive care unit.  
Materials and Methods: In this clinical trial study, 60 patients undergoing 
coronary artery bypass graft surgery were divided into two groups (N=30): 
the first group receiving Morphine and the second group receiving 
Dexmedetomidine. At admission to the ICU in the first group, Morphine was 
injected at a dose of 0.25 mg/kg, and in the second group, Dexmedetomidine 
was injected at a dose of 1 μg/kg for 10 minutes. Hemodynamic parameters 
and blood gas levels at preoperative cardiac care were compared between the 
two groups at the time of endotracheal tube withdrawal.  
Results: The trend of hemodynamic changes and blood gas levels during 
the intensive care unit stay did not differ between the two groups. The mean 
duration of mechanical ventilation in the Morphine group was 10.63/2 2.31 
hours and in the Dexmedetomidine group was 9.77/1 1.92 hours, and there 
was no significant difference between the two groups (p=0.12).  
Conclusion: both Morphine and Dexmedetomidine had similar effects on 
hemodynamic stability and blood gas levels; however, Dexmedetomidine 
was associated with fewer drug-related side effects; so, it seems wise to 
consider Dexmedetomidine superior to Morphine in the postoperative period 
of CABG patients.  
Keywords: Coronary artery bypass, Hemodynamic, Extubation of the airway, 
Dexmedetomidine, Morphine 
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Introduction 
Following open-heart surgery, patients are directly 
transferred to the intensive care unit, where they are 
carefully monitored until they regain consciousness 
from anesthesia, and adequate oxygenation and 
hemodynamic stability are achieved (1). Early 
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extubation is one of the chief measures for reducing 
complications in the patients and shortening the 
length of stay in the recovery room (2). Early 
extubation effectively reduced the detrimental effects 
of positive pressure ventilation by shortening the 
duration of mechanical ventilation. Also, its general 
effects include patient comfort, reduction in 
respiratory complications, ease of patient monitoring 
and management, faster patient ambulation and 
facilitation of movement and activity, and lower 
hospitalization costs (3). Early extubation results in 
increased left ventricular filling, improved ventricular 
function, and consequently, increased cardiac output 
(3). Moreover, this measure has several positive 
effects on the respiratory system, including reducing 
the risk of nosocomial pneumonia and damage to the 
lung tissue (4). 
The alpha-2 agonist Dexmedetomidine has 
multiple desirable properties, including analgesic 
effects, inhibition of the sympathetic output, 
anxiolytic effects, and reduction of norepinephrine 
levels. These effects contribute to the patient 
improvement and hemodynamic stability (5, 6). 
Dexmedetomidine treatment of Oxygen-Glucose 
deprivation/ reoxygenation (OGD/R) cells promoted 
cell survival and attenuated OGD/R-induced cell 
apoptosis, and it might be an effective agent for the 
treatment of ischemic diseases. Dexmedetomidine 
protects WRL-68 cells against OGD/R-induced injury 
by inhibiting inflammation, oxidative stress, and cell 
apoptosis via the activation of the Nrf2/HO-1 
signaling pathway (7). 
Morphine is used as an analgesic for pain relief 
in hospitalized and cardiac patients and against pain 
during the surgery and in the post-surgery period (8). 
The present study was conducted to compare 
the effects of Dexmedetomidine and Morphine as 
pain-relief and sedative agents in the intensive care 
unite (ICU) and to determine which of these two 
medications involves fewer complications, shorter 
times to extubation, better ABG parameters, shorter 
ICU stays, and greater hemodynamic stability in 
patients after coronary artery bypass graft (CABG). 
CABG is a lengthy procedure and involves a vital part 
of the body. Therefore, patients undergoing CABG 
under general anesthesia are at the risk of a multitude 
of problems, including hemodynamic instability, 
imbalances of fluid, electrolytes, and blood gases, 
coagulation disorders, and late extubation, each of 
which can affect the quality of the surgery and cause 
further complications and increase patient mortality 
(9). Thus, it is hypothesized that using 
Dexmedetomidine can lead to earlier extubation and 
improved respiratory parameters, and reduce CABG 
complications. 
Results of this study can contribute to the 
subject because currently (also where this study did) 
Morphine is commonly used for post-surgical pain 
relief, and to date, a few comprehensive studies have 
been performed to investigate the effects of 




The present double-blind clinical trial study was 
approved by the Ethics Committee of Isfahan 
University of Medical Sciences (Code: 
IR.MUI.MED.REC.1398.016), registered at Iran's 
Clinical Trial Registration Center (Code: 
IRCT20130311012782N39), and conducted in the 
years 2017 and 2018 in Shahid Chamran Teaching 
Hospital in the city of Isfahan. The study population 
consisted of CABG surgery candidate patients 
admitted to the hospital. 
The criteria for the patients' inclusion in this 
clinical trial were: candidates for CABG, patient's 
consent to take part in the study, no addiction to 
opioids, no use of psychotropic or antidepressant 
medications, no underlying respiratory diseases, and 
no use of medications affecting the hemodynamic 
status. 
The exclusion criteria were: pumping time over 
120 minutes, patients requiring surgeries other than 
CABG, the need for aortic balloon pump, return to the 
operating room due to re-bleeding, patients needing 
more than two inotropic medications before 
separation from the cardiopulmonary pump, changes 
of surgery plan in terms of the surgical techniques, 
and emergency surgery. 
After obtaining written informed consent, 
patients were visited the night before surgery by the 
anesthesiologist. In this study, data obtained from the 
patients were randomized using random allocation 
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software. To achieve uniformity in the study, the 
same pre-medication and anesthesia induction and 
continuation methods were applied in the two groups. 
After CABG surgery, the patients were transferred to 
ICU. The first ABG sample was obtained upon the 
establishment of monitoring and mechanical 
ventilation.  
Baseline systolic and diastolic hemodynamics 
and pulse rate were recorded. In the first group of 
patients, 0.25 mg/kg Morphine, dissolved in 50 mL's 
of normal saline, was administered by infusion over 
ten minutes at admission to the recovery room. In the 
second group, one µg/kg of Dexmedetomidine was 
infused into the patients over ten minutes. The first 
group was infused with a dose of 50 mL's normal 
saline, and the second group with one µg/kg of 
Dexmedetomidine per hour in 50 mL's normal saline. 
In both groups, three mg of Morphine was 
administered to the patients that needed more 
analgesics by orders from the anesthesiologist. 
In the present study, the double-blinding 
method was applied as follows: patients did not know 
which type of medication they were receiving. 
Moreover, medications were prepared in coded 
syringes of similar shape by one of the operating 
room staff who had no knowledge of this study's 
particulars and then given to a study operator with no 
knowledge of the contents of the syringes to be 
administered. 
Hemodynamic parameters, including systolic 
and diastolic blood pressures, the mean arterial 
pressure, the heart rate, and the level of the blood 
gases (Paco2, Pao2, and pH) were determined and 
recorded before surgery, at admission to ICU, during 
the stay at the ICU, and during extubation, in both 
groups of patients. Furthermore, medication side-
effects were assessed and recorded, including nausea, 
vomiting, hemodynamic disturbances (hypertension, 
hypotension, bradycardia, and tachycardia), and 
respiratory depression, during the study. Finally, the 
patients' demographic details, ICU stay duration, 
blood products, and inotropes received were recorded 
in data collection forms. 
The sample size was determined as 30 patients 
per group; we considered the following parameters in 
the calculation: 95% confidence interval, a test power 
of 80%, an estimated standard deviation of about 1.17 
hours for the extubation time, and a minimum 
significant difference of 0.8 between the two groups. 
Figure 1 shows the flowchart of the present study. 
The collected data were entered into the 
computer and analyzed in SPSS-24, using Chi-
squared test (to compare qualitative and nominal data 
in the two groups), T-test (to compare quantitative 
data in the two groups), and variance analysis with 
repeated measures (to assess the trend of changes in 
variables over time in the two groups). 
 
Results 
In the present study, 60 patients undergoing CABG 
surgery received either Morphine or 
Dexmedetomidine in two separate groups (30 patients 
in each) and were studied. No patients were removed 
from the study because of unwanted complications. 
There were no significant differences between the two 
groups regarding demographic and general variables 
(Table 1).  
Table 1: Demographics and Baseline Variables in Study Groups (Dexmedetomidine & Morphine). 
 
Demographic Variables P 
Case Group 
Morphine Dexmedetomidine 





Female 10(33.3) 10(33.3) 
Weight (Kg) 0.6 75.1±16.5 77.1±12.2 
Duration of Mechanical 
Ventilation Pump 
0.59 32.8±90.3 94.8±25.7 
Duration of Aortic Clamp 0.24 64.3±32.3 55.9±18.8 
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Assessment of hemodynamic parameters 
before surgery, at admission to ICU, during the stay 
in ICU, and at the time of extubation showed no 
significant differences between the two groups 
receiving Morphine and Dexmedetomidine in terms 
of the systolic and diastolic blood pressures, the mean 
pressure, and the heart rate. Furthermore, intragroup 
assessments showed no significant changes in these 
Table 2: Mean ± Standard Deviation of Blood Pressure and Heart Rate between the two Study Groups (Morphine & 
Dexmedetomidine). 
 




Systolic Blood Pressure 
(mmHg) 
Pre –operation 119.5±9.6 116.8±12.1 0.33 
Upon Entering the ICU 112.3±12.2 116.1±9 0.18 
During the ICU Stay 116.1±10.4 116.2±7.5 0.96 
At the time of the Extubation 119.3±14.4 114±1.4 0.62 
P 0.34 0.1 0.061 
Diastolic Blood Pressure 
(mmHg) 
Pre –operation 66.7±10 71.8±8.4 0.23 
Upon Entering the ICU 62.8±9.9 61.5±7.4 0.56 
During the ICU Stay 62.7±8.7 5.61±7.4 0.84 
At the time of Extubation 63.7±9.9 69±5.7 0.47 
P 0.31 0.68 0.09 
Mean Arterial Pressure 
(mmHg) 
Pre-Operation 82.4±11.7 78.6±9.9 0.2 
Upon Entering the ICU 76.7±12.1 81.5±10.8 0.12 
During the ICU Stay 78.1±8.8 81.1±7.5 0.18 
At the time of Extubation 75.5±11.3 77.5±10.6 0.81 
P 0.81 0.87 0.06 
Heart Rate 
(N/h) 
Pre-Operation 84.3±12.3 88.6±10.6 0.15 
Upon Entering the ICU 88±13.5  91.9±10.2 0.21 
During the ICU Stay 91.6±11.2 92.9±11 0.67 
At the time of Extubation 85.3±23.8 87.5±9.2 0.9 
P 0.62 0.19 0.092 
 
 
Table 3: Mean ± Standard Deviation of Blood Gas Variables between the two Study Groups (Morphine & 
Dexmedetomidine). 





Pre-Operation 7.42±0.07 7.4±0.04 0.18 
Upon Entering the ICU 7.26±0.74 7.32±0.55 0.69 
During the ICU Stay 7.36±0.19 7.37±0.16 0.9 
At the time of Extubation 7.45±0.18 7.31±0.01 0.32 
P value 0.11 0.13 0.1 
PaO2 (mmHg) 
 
Pre-Operation 96.1±297.7 259.6±151.6 0.2 
Upon Entering the ICU 122.4±310.3 308.8±117.9 0.96 
During of stay in ICU 133.4±51 125.5±45.6 0.53 
At the time of Extubation 119.4±35 91.1±1.6 0.29 
P value 0.99 0.52 0.15 
PaCO2 (mmHg) 
Pre-Operation 33.9±5.7 34.9±5.2 0.46 
Upon Entering the ICU 34±6.1 34.4±7.4 0.86 
During the ICU Stay 36.9±5.3 40±13.6 0.26 
At the time of Extubation 36.7±11.1 37.8±3.9 0.9 




Pre-Operation 24.1±7.2 22.1±1.6 0.13 
Upon Entering the ICU 22±1.9 22±1.7 0.92 
During of stay in ICU 23.5±4.2 22.1±1.7 0.09 
At the time of Extubation 22.7±2.3 22±1.3 0.65 
P value 0.23 0.11 0.09 
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parameters within the groups over time. Finally, 
intergroup assessments revealed no significant 
difference between the two groups regarding the trend 
of changes in hemodynamic parameters (Table 2). 
The mean duration of mechanical ventilation in 
the Morphine receiving group infusion was 
10.63±2.31 hours, and in the Dexmedetomidine 
receiving group infusion was 9.77±1.92 hours. Thus, 
the difference between the two groups in terms of 
ventilation duration was negligible and not significant 
(p=0.12). Assessment of blood gases showed no 
significant difference between the Morphine and 
Dexmedetomidine groups for the mean levels of 
blood gases PaO2, PaCO2, HCO3, and pH. Moreover, 
intragroup and intergroup assessments showed no 
significant differences within the groups or between 
the two groups in the trends of change in blood gases 
(Table 3). 
Table 4 presents the frequency distribution of 
receiving blood products and inotropes and post-
surgery complications in the Morphine and 
Dexmedetomidine groups. The results showed no 
significant difference between the two groups in 
terms of receiving inotropes and blood products. Most 
importantly, regarding post-surgery complications, 
the vomiting frequency was significantly higher in the 
Morphine group (p=0.024). 
 
Discussion 
The present study found fewer complications, shorter 
extubation times, improved blood gas analysis 
parameters, shorter ICU stay, and improved 
hemodynamic stability in CABG patients receiving 
dexmedetomidine compared with morphine in the 
postoperative period; while there was no significant 
difference between the two groups in terms of 
demographic and baseline variables. However, the 
results showed neither morphine nor 
dexmedetomidine do not adversely affect the 
regaining of respiratory function in the patients. The 
results of the present study are consistent with several 







Receipt of Blood Products 
Packed Cells 12(40%) 12(40%) 1 
FFP 5(16.7%) 6(20%) 0.99 
Platelet 1(3.3%) 2(6.7%) 0.99 
Crayo 0(0%) 0(0%) 1 
Receipt of Inotrop 
Adrenaline 2(6.7%) 0(0%) 0.49 
Dobutamine 3(10%) 0(0%) 0.24 
Noradrenaline 3(10%) 1(3.3%) 0.61 
Post-operation side effects 
Vomit 5(16.7%) 1(3.3%) 0.2 







Figure 1. Study Flowchart. 
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other studies regarding the severity of post-surgery 
pain and the needed rescue analgesics (10), 
postoperative need for beta-blockers, and antiemetics 
(11), duration of mechanical ventilation (12), 
psychological, hemodynamic, and coagulative 
outcome measures (13), myocardial oxygenation, 
cardiac oxygen demand, myocardial protection, and 
post-surgical mortality (5-6), the need for a 
postoperative required dose of sedatives and 
analgesics (14); besides, there are numerous studies 
which have assessed the molecular mechanism of 
Dexmedetomidine leading to the latter clinical 
outcomes; which could support the clinical findings. 
The research of cellular and molecular of 
Dexmedetomidine's effects show that the protection 
of Dexmedetomidine against Oxygen-Glucose 
deprivation/reoxygenation Injury-Induced Apoptosis 
via the p38 MAPK/ERK Signaling Pathway show that 
Dexmedetomidine treatment of OGD/R cells 
promoted cell survival and attenuated OGD/R-
induced cell apoptosis. It also activated the p38 
MAPK/ERK signaling pathway, increased the levels 
of Bcl-2, and decreased the levels of Bax and cleaved 
caspase-3. Treatment with the p38 MAPK/ERK 
inhibitor CV-65 inhibited p38 MAPK/ERK activation 
and abrogated the Dexmedetomidine-induced effects 
on cell survival and apoptosis. Moreover, as a result, 
Dexmedetomidine protects N2A cells from OGD/R-
induced apoptosis via the p38 MAPK/ERK signaling 
pathway activation. Dexmedetomidine might be an 
effective agent for the treatment of ischemic diseases 
(7). 
Also, in other cellular and molecular research, 
Dexmedetomidine promoted cell viability and 
suppressed cell apoptosis in OGD/R-treated WRL-68 
cells. It reduced TNF-α, IL-6, IL-1β, ROS, and MDA 
production, whereas it increased SOD and GSH-Px in 
OGD/R-treated WRL-68 cells. Moreover, Nrf2, HO-
1, and Bcl-2 expression were upregulated, whereas, in 
contrast, transcripts for Bax, caspase3, and caspase9 
were downregulated following Dexmedetomidine 
treatment under OGD/R. Knockdown of Nrf2 
reversed the Dexmedetomidine, effects on cell 
proliferation, apoptosis, and expression of TNF-α, IL-
6, IL-1β, ROS, MDA, SOD, and GSH-Px. 
Dexmedetomidine protects WRL-68 cells against 
OGD/R-induced injury by inhibiting inflammation, 
oxidative stress, and cell apoptosis via the activation 
of the Nrf2/HO-1 signaling pathway, suggesting that 
it may be a potential protector against hepatic injury 
(15). 
Dexmedetomidine has been administered 
worldwide in the last few years. Some studies suggest 
positive effects of this medication in maintaining the 
patients' hemodynamic balance. Although using 
Morphine can also be beneficial, it seems that the 
benefits of Dexmedetomidine outweigh Morphine in 
patients undergoing CABG, especially the elderly and 
those with underlying diseases. 
Given the limitations of the present study, 
including the small sample size, it is recommended 
that future studies investigate larger samples and use 
the findings of the present study as a basis for further 
investigations on the effect of Dexmedetomidine use 
on the duration of mechanical ventilation and the 
maintenance of hemodynamic stability. Furthermore, 
the present study focused on the impact of 
Dexmedetomidine in CABG surgery; however, it is 
recommended that the effects of this medication in 
other types of surgery are also studied. 
 
Conclusion 
The results show that both Morphine and 
Dexmedetomidine have similar effects in maintaining 
hemodynamic stability and the blood gases' level. 
Still, Dexmedetomidine would be preferable to 
Morphine because it has few side-effects. Thus, our 
hypothesis, suggesting a reduction in CABG surgery 
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